

Notification Date: September 23, 2025 Effective Date: November 4, 2025

# Cytomegalovirus Antibody, IgM, Serum

Test ID: CMVMS

**Useful for:** 

Aiding in the diagnosis of acute infection with cytomegalovirus

**Methods:** 

Electrochemiluminescence Immunoassay (ECLIA)

**Reference Values:** 

Negative

Reference values apply to all ages.

Specimen Requirements:

Supplies: Sarstedt Aliquot Tube 5 mL (T914)

**Collection Container/Tube:** 

**Preferred:** Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.6 mL

Minimum Volume: 0.6 mL

**Collection Instructions:** Centrifuge and aliquot serum into a plastic vial

## **Specimen Stability Information:**

Specimen Type	Temperature	Time
Serum	Refrigerated (preferred)	28 days
	Ambient	7 days
	Frozen	90 days

#### Cautions:

- Sera collected very early during the acute stage of infection may have undetectable levels of cytomegalovirus (CMV) IgM.
- The CMV IgM assay should not be used alone to diagnose CMV infection. Results should be considered in conjunction with clinical presentation, patient history, and other laboratory findings. In cases of suspected disease, submit a second specimen for testing in 10 to 14 days.

- The detection of CMV-specific IgM antibodies in a single sample is not sufficient to prove an acute infection. In single cases elevated IgM antibody levels may persist even for years after initial infection.
- Performance characteristics have not been evaluated in immunosuppressed patients or organ transplant recipients and have not been established for cord blood or for testing of neonates. Immunocompromised patients may have impaired immune responses and nonreactive IgG results may be due to delayed seroconversion and, therefore, do not rule out current infection.
- Sera from patients with primary EBV infections can demonstrate positive results in the Elecsys CMV IgM
  assay. This is not unexpected as both viruses belong to the herpes virus family and this potential
  interference is known for the CMV IgM assays. Potential cross-reactivity with autoimmune markers and
  antibodies against influenza vaccination could not be ruled out. As with many micro-capture assays, an
  interference with unspecific IgM is observed. Increasing amounts of unspecific IgM may lead to a decrease
  in the recovery of positive samples with the Elecsys CMV IgM assay.
- Samples should not be taken from patients receiving therapy with high biotin doses (ie, >5 mg/day) until at least 8 hours following the last biotin administration.

## **CPT Code:**

86645

**Day(s) Performed:** Monday through Saturday **Report Available:** Same day/1 to 3 days

### Questions

Contact Dunisha Messmer, Laboratory Resource Coordinator at 800-533-1710.